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Abstract We present a user-friendly visual representation
of The National Institute of Allergy and Infectious Disease
and the Food Allergy and Anaphylaxis Network criteria so
as to enhance recognition of anaphylaxis and active
teaching and learning.
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Anaphylaxis is a potentially fatal acute systemic allergic
reaction. It is becoming increasingly common. [1, 2]
Multiple studies have shown that anaphylaxis is both
under-recognized and under-treated. [3–5]
Anaphylaxis is known to have varied presentations
involving different organ systems. There are no universally
accepted criteria for diagnosis of anaphylaxis. Lack of
standardized diagnostic criteria has hampered diagnosis and
management of anaphylaxis. The National Institute of
Allergy and Infectious Disease and the Food Allergy and
Anaphylaxis Network (NIAID/FAAN) organized an inter-
national symposium in 2005 at which new diagnostic
criteria for anaphylaxis were proposed. Although not
prospectively validated, these criteria provide physicians
with a rapid and simplified means of making the diagnosis.
Traditionally, the term ‘anaphylaxis’ referred to life-
threatening manifestations of allergic reactions, such as
respiratory distress or shock (anaphylactic shock) as
manifested by hypotension or signs of hypoperfusion of
critical organs. However, there is now a growing consensus
that anaphylaxis is a systemic allergic reaction that typically
involves more than one organ system but rarely can present
with cardiovascular compromise as the only symptom.
Therefore, the new criteria will capture broader presenta-
tions, encompassing less severe manifestations.
The importance of recognition and diagnosis of mild
presentations of anaphylaxis (for example, rash and vomit-
ing after an allergen exposure) is underscored by a study by
Pumphrey. [6] In this study of 139 fatalities due to
anaphylaxis, 78% of deaths attributed to food allergy, and
82% of deaths attributed to venom allergy occurred in
patients with no previous history of severe allergic
reactions. These fatalities might have been prevented if
the previous less severe presentations had been recognized
and patients had been provided with self-injectable epi-
nephrine and appropriate follow-up referrals.
Table 1 shows the NIAID/FAAN criteria. [7] Patients are
likely to have anaphylaxis if any one of the three criteria is
present. It was believed that the criteria would “capture
more than 95% of cases of anaphylaxis”.[ 7]
We present a user-friendly visual representation (Fig. 1)
of the NIAID/FAAN criteria so as to enhance, not only
recognition of anaphylaxis, but also active teaching and
learning of these criteria among health-care providers.
Increased recognition and diagnosis of anaphylaxis will
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Fig. 1 Visual representation of the National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network criteria for
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Table 1 National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network criteria for anaphylaxis
Anaphylaxis is likely when any one of these three criteria is fulfilled:
1. Acute onset of illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both (e.g., generalized hives, pruritus or
flushing, swollen lips, tongue, or uvula)
and at least one of the following:
(a) Respiratory compromise (e.g., dyspnea, wheeze or bronchospasm, stridor, reduced peak expiratory flow, hypoxemia)
(b) Reduced blood pressure or associated symptoms of end-organ dysfunction (e.g., hypotonia [collapse], syncope, incontinence)
2. Two or more of the following that occur rapidly after exposure to a likely allergen for that patient (minutes to several hours):
(a) Involvement of the skin or mucosal tissue (e.g., generalized hives, itch or flush, swollen lips, tongue, or uvula)
(b) Respiratory compromise (e.g., dyspnea, wheeze or bronchospasm, stridor, reduced peak expiratory flow, hypoxemia)
(c) Reduced blood pressure or associated symptoms (e.g., hypotonia [collapse], syncope, incontinence)
(d) Persistent gastrointestinal tract symptoms (e.g., crampy abdominal pain, vomiting)
3. Reduced blood pressure after exposure to known allergen for that patient (minutes to several hours):
(a) Infants and children: low systolic blood pressure (age specific) or >30% decrease in systolic blood pressure
a
(b) Adults: systolic blood pressure <90 mmHg or >30% decrease from that person’s baseline
a Low systolic blood pressure for children is defined as <70 mmHg from 1 month to 1 year, < (70 mmHg + [2 × age]) from 1 to 10 years, and
<90 mmHg from 11 to 17 years.
Modified from Sampson et al. [7]
4 Int J Emerg Med (2009) 2:3–5hopefully lead to improved management and better out-
comes in patients suffering from anaphylaxis.
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